/L and CD4/ CD8 ratio of 0.51. The patient also had a history of hepatitis C and had failed IFN and ribavirin treatment 5 years earlier, with a viral load of 1 Â 10 7 IU/mL at the time of AML diagnosis.
Initial induction was with cytarabine and idarubicin (Little Ic), achieving partial response. Subsequent salvage with fludarabine, cytarabine and idarubicin (FLAG-Ida) achieved CR and was followed by a further consolidation cycle with high-dose cytarabine (HiDAC). Given the high risk of relapse, further consolidation with an auto-SCT was planned. A matched sibling donor was not used for allogeneic transplant, owing to high risk. Peripheral stem cells were collected (6.5 Â 10 6 CD34/kg) post HiDAC consolidation, stimulated with G-CSF. BU and melphalan conditioning was given and 3.2 Â 10 6 CD34/kg stem cells were infused.
Neutrophils engrafted at day 14 post auto-SCT; however, platelets failed to engraft, remaining below 20 Â 10 9 /L. A clear cause for the delayed platelet engraftment was not found. BM biopsy confirmed remission, with normal megakaryocyte numbers. Viral loads for HIV, hepatitis C and hepatitis B were unchanged. Antiretrovirals were temporarily ceased, with no change in platelet numbers, though this did provoke a temporary rise in HIV RNA viral load. An abdominal ultrasound excluded hypersplenism. Anti-platelet Ab screening with solid-phase red-cell adherence and mAb immobilization of platelet Ag was negative. A further infusion of remaining stem cells failed to improve platelet counts. Post-transplant T-and B-lymphocyte subsets had changed. The absolute CD4 count had decreased to 144 Â 10 6 /L, while the CD8 count had increased to 43000 Â 10 6 /L. CD19 B-cells were reduced, at o36 Â 10 6 /L.
Autoimmune thrombocytopenia was suspected. Standard therapy for autoimmune thrombocytopenia was ineffective and included high-dose prednisolone, i.v. Ig and rituximab ( Figure 1 ). The thrombopoietic growth factor romiplostim was commenced at day 80, at a dose of 375 mcg weekly. Platelet counts rose to 420 Â 10 9 /L at day 111, obviating the need for splenectomy. Platelet counts continued to rise and the frequency of romiplostim administration was reduced and gradually withdrawn, with platelet count remaining 4100 Â 10 9 /L. From commencement of romiplostim, the patient received 21 doses over 150 days. Platelet recovery shortly after commencement of romiplostim was in keeping with response to therapy. The patient remains in remission, with platelets in the normal range 15 months post transplant.
Whether the incidence of AML in the HIV-positive population has increased is unclear, though overall it remains rare. 1 As a result, optimal treatment for AML in the HIV-positive patient has not been established; however, auto-SCT consolidation is associated with more durable responses. Thrombocytopenia post-auto-SCT is a recognized phenomenon that has not been documented in this group.
In standard populations undergoing SCT, delayed platelet engraftment of 490 days occurs in 5% of cases. 2 There are numerous causes, including drugs, hypersplenism, low CD34 counts in the graft, disease relapse and autoimmune disease. An autoimmune cause seemed the most likely cause in our patient after exclusion of other causes. His CD4/CD8 ratios decreased post transplant despite an overall increase in T-cells, which is consistent with other case series of autoimmune thrombocytopenia post SCT. 3 Studies suggest that immune dysregulation post transplant may be the cause of autoimmune phenomena post transplant. Although the exact mechanisms have not been identified, abnormal T-cells have been implicated, either self-recognizing autoreactive cytotoxic T-cells or an impaired suppressive function of T regulatory cells. 3 In our case, HIV or the hepatitis C virus may have induced autoreactive T-cells, which, in the setting of an abnormally reconstituting immune system with decreased CD4 T regulatory cells, precipitated autoimmune thrombocytopenia. Both HIV and hepatitis C virus are well known to be associated with autoimmune complications. 4, 5 In most documented cases of autoimmune thrombocytopenia post-SCT, first-line treatment with steroids has been ineffective, with several cases requiring i.v. Ig and splenectomy. In order to avoid splenectomy, we used the thrombopoietic growth factor, romiplostim, to maintain platelet counts as a bridge while the autoimmune thrombocytopenia resolved.
Romiplostim is effective in increasing platelet counts in refractory idiopathic thrombocytopenic purpura and has been trialled in delayed platelet recovery post-SCT. 6, 7 Use of romiplostim in our patient correlated with an increase in platelets to the normal range when immunomodulatory agents had failed. On tapering and cessation of romiplostim, platelet counts were maintained. In HIVpositive patients, post-SCT lymphocyte subsets return to baseline at approximately 6 months. 8 In our patient we hypothesize that autoimmunity resolved following immune reconstitution.
Autoimmune thrombocytopenia following auto-SCT in the setting of HIV infection is a rare complication, which may be related to immune dysregulation post transplant in conjunction with viral infection. Romiplostim can increase platelet counts, reducing the need for platelet transfusion and splenectomy until the resolution of autoimmune thrombocytopenia and immune reconstitution. Figure 1 Platelet count post-SCT and treatments for autoimmune thrombocytopenia.
